Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III study of monotherapy by gemcitabine or vinorelbine comparing to doublet by carboplatin and paclitaxel among elderly patients with stage IIIB/IV NSCLC (obligatory second-line by erlotinib).

Next Previous
Search
Trial Profile

Phase III study of monotherapy by gemcitabine or vinorelbine comparing to doublet by carboplatin and paclitaxel among elderly patients with stage IIIB/IV NSCLC (obligatory second-line by erlotinib).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Erlotinib (Primary) ; Paclitaxel (Primary) ; Gemcitabine; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

Most Recent Events

  • 02 Oct 2012 Results reporting outcomes for second-line erlotinib presented at the 37th Congress of the European Society for Medical Oncology.
  • 08 Aug 2011 Primary endpoint 'Overall-survival' has been met.
  • 08 Aug 2011 Results after 30.3 months of follow-up published in the Lancet.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top